|GOG 0225||IRB 12-869||
Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?
||Fairview, Hillcrest, Main Campus||Stage 2, Stage 3, Stage 4|| ||Fallopian Tube, Gynecologic, Ovarian, Peritoneal
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advance Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary
||Fairview, Hillcrest, Main Campus||Recurrent, Stage 2, Stage 3, Stage 4||Phase 2||Gynecologic, Ovarian
A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) in recurrent/persistent ovary, fallopian tube, primary peritoneal, endometrial, or endometriosis-associated clear cell carcinoma characterized for the retention or loss of BAF250a Expression
||Fairview, Hillcrest, Main Campus|| ||Phase 2||Gynecologic, Ovarian
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrentand Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous EpithelialOvarian, Fallopian Tube, or Primary Peritoneal Cancer
||Fairview, Hillcrest, Main Campus||Stage 2, Stage 3, Stage 4||Phase 3||Fallopian Tube, Gynecologic, Ovarian, Peritoneal
A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab (NSC #704865, IND #7921) and CTEP-Supplied Agent ABT-888 (NSC#737664, IND #77840) in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube or primary peritoneal cancer
||Hillcrest, Main Campus||Stage 2, Stage 3, Stage 4||Phase 1||Fallopian Tube, Gynecologic, Ovarian, Peritoneal
A Randomized, Open-Label Study Comparing the Combination of YONDELIS, and DOXIL/CAELYX,With DOXIL,/CAELYX, Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
||Fairview, Hillcrest, Main Campus||Recurrent||Phase 3||Fallopian Tube, Gynecologic, Ovarian, Peritoneal
MORAb-003-011, A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
||Fairview, Hillcrest, Main Campus||Recurrent||Phase 2||Fallopian Tube, Gynecologic, Ovarian, Peritoneal